320 E Vine Drive
Ventria Bioscience is the first company to commercialize recombinant proteins derived from a plant-based manufacturing system. Ventria’s lead product is Ven100 in a Phase III clinical program to prevent antibiotic associated diarrhea (AAD). Ventria’s platform, ExpressTec, is a safe, affordable, and sustainable manufacturing technology that achieves recombinant protein yield that is many times higher than alternative systems. As a result of this advantage, Ventria’s products are accessible globally.
Ventria has commercialized nine products in three business segments, including human health, zoonotic disease, and cell-based biomanufacturing.
Ventria’s human health products include Ven100 targeting AAD in at-risk adults. The target market for Ven100 is long term care patients and hospital in-patients who are prescribed broad-spectrum antibiotics. There are 22 million antibiotic prescriptions written for hospital in-patients and 4 million written in long term care.
Other products in development include products targeting ulcerative colitis and osteoporosis.
Ventria also produces several recombinant proteins and peptides for use in the cell culture and biomanufacturing market. These products are designed to optimize performance and eliminate animal components and blood products in biomanufacturing, cell-based vaccines, cellular therapy, and regenerative medicine. These products are marketed under the Company’s InVitria Division (www.InVitria.com)
Ventria employs a patented plant-based manufacturing technology,ExpressTec, for recombinant protein production. ExpressTec has been shown to achieve target protein yields that are more the ten-fold higher than other plant-based systems providing significant economic advantages. Ventria currently manufactures under cGMP standards at its 44,000 square foot dedicated manufacturing facility in Junction City, Kansas.
Ventria Board of Directors
A world-renowned biotechnology and industry leading Board of Directors champion Ventria’s mission of developing products for global markets in human health, cell-based biomanufacturing, and zoonotic disease. Ventria’s leaders have amassed over 120 years of biotech experience, registered over 145 U.S. and foreign patents, and published over 600 scientific papers.
Board Members include:
• Dominique F. Baly, Board Member
• Melvin D. Booth, Board Member
• William W. Crouse, Board Member
• Scott E. Deeter, Board Member, President & CEO
• David Dwyer, Board Member
• William H. Rutter, Esq., Board Member
• William J. Rutter, Ph.D., Board Member
• Thomas N. Urban, Chairman
• Pablo Valenzuela, Ph.D., Board Member
Contribution to Research
Ventria fosters academic research by providing an opportunity for academic and government researchers to gain access to recombinant proteins and peptides for their research. In the past, it has been difficult for researchers to conduct extensive studies on recombinant proteins or peptides because these materials were cost prohibitive and sufficient quantities were not readily available. To respond to these needs, Ventria created a BioShare program, which allows qualified researchers the opportunity to receive samples of recombinant human proteins, including albumin, lactoferrin, lysozyme and transferrin.
Interested researchers should visit Ventria’s website at http://www.ventria.com/bioshare